Oral Sucrosomial Iron Is as Effective as Intravenous Ferric Carboxy-Maltose in Treating Anemia in Patients with Ulcerative Colitis

Autor: Nicola de Bortoli, Federico Zanzi, Santino Marchi, Domenico Tricò, Giovanni Baiano Svizzero, Massimo Bellini, Corrado Blandizzi, Francesca Coppini, Luca Antonioli, Lorenzo Bertani
Rok vydání: 2020
Předmět:
Male
Comparative Effectiveness Research
Administration
Oral
Gastroenterology
Ferric Compounds
clinical
Hemoglobins
0302 clinical medicine
Prospective Studies
Ferric Oxide
Saccharated
Nutrition and Dietetics
biology
medicine.diagnostic_test
Anemia
Iron-Deficiency
Iron deficiency
Middle Aged
anemia
Ulcerative colitis
Treatment Outcome
Tolerability
030220 oncology & carcinogenesis
Serum iron
030211 gastroenterology & hepatology
Administration
Intravenous
Female
lcsh:Nutrition. Foods and food supply
medicine.drug
Adult
medicine.medical_specialty
Anemia
Iron
Clinical
lcsh:TX341-641
Article
03 medical and health sciences
Internal medicine
medicine
Humans
Maltose
ulcerative colitis
Aged
business.industry
medicine.disease
Ferritin
Ferritins
biology.protein
Hematinics
Ferric
Colitis
Ulcerative
Hemoglobin
business
Food Science
Zdroj: Nutrients
Volume 13
Issue 2
Nutrients, Vol 13, Iss 608, p 608 (2021)
ISSN: 2072-6643
Popis: Anemia is a frequent complication of ulcerative colitis, and is frequently caused by iron deficiency. Oral iron supplementation displays high rates of gastrointestinal adverse effects. However, the formulation of sucrosomial iron (SI) has shown higher tolerability. We performed a prospective study to compare the effectiveness and tolerability of oral SI and intravenous ferric carboxy-maltose (FCM) in patients with ulcerative colitis in remission and mild-to-moderate anemia. Patients were randomized 1:1 to receive 60 mg/day for 8 weeks and then 30 mg/day for 4 weeks of oral SI or intravenous 1000 mg of FCM at baseline. Hemoglobin and serum levels of iron and ferritin were assessed after 4, 8, and 12 weeks from baseline. Hemoglobin and serum iron increased in both groups after 4 weeks of therapy, and remained stable during follow up, without significant treatment or treatment-by-time interactions (p = 0.25 and p = 0.46 for hemoglobin, respectively
p = 0.25 and p = 0.26 for iron, respectively). Serum ferritin did not increase over time during SI supplementation, while it increased in patients treated with FCM (treatment effect, p = 0.0004
treatment-by-time interaction effect, p = 0.0002). Overall, this study showed that SI and FCM displayed similar effectiveness and tolerability for treatment of mild-to-moderate anemia in patients with ulcerative colitis under remission.
Databáze: OpenAIRE
Externí odkaz: